JCOGの基本情報 > 研究実績 > 骨軟部腫瘍グループ

JCOGの基本情報骨軟部腫瘍グループ

更新日:2015年9月17日

  1. 論文
    1. 委員会承認の治療研究
      K Tanaka, Y Iwamoto, et al.: Preoperative and postoperative chemotherapy with ifosfamide and adriamycin for adult high-grade Soft-tissue Sarcomas in the Extremities: Japan Clinical Oncology Group Study JCOG0304. Jpn J Clin Oncol. 39(4): 271-273, 2009.
      K Kataoka, K Tanaka, Y Iwamoto, et al.: Soft-tissue Sarcomas in the Extremities: A Randomized Phase II/III Trial of Perioperative Chemotherapy with Adriamycin Plus Ifosfamide Versus Gemcitabine Plus Docetaxel for High-grade Soft Tissue Sarcoma: Japan Clinical Oncology Group Study JCOG1306. Jpn J Clin Oncol. 44(8): 765-769, 2014.
      K Tanaka, J Mizusawa, Y Iwamoto, et al.: Perioperative chemotherapy with high-dose ifosfamide and doxorubicin for high-grade soft tissue sarcomas in the extremities: Japan Clinical Oncology Group Study JCOG0304. Jpn J Clin Oncol. 45: 555-561, 2015.
    2. グループ代表者管理の治療研究
      Y Iwamoto, K Tanaka, et al.: Multiinstitutional phase II study of neoadjuvant chemotherapy for osteosarcoma (NECO study) in Japan: NECO-93J and NECO-95J. J Orthop Sci. 14(4): 397-404, 2009.
    3. 附随研究等
      Y Oda, Y Iwamoto, et al.: Chemokine receptor CXCR4 expression is correlated with VEGF expression and poor survival in soft-tissue sarcoma. Int J Cancer. 124(8): 1852-1859, 2009.
      C Fukukawa, J Toguchida, et al.: Activation of the non-canonical Dvl-Rac1-JNK pathway by Frizzled homologue 10 in human synovial sarcoma. Oncogene. 28(8): 1110-1120, 2009.
      K Kohashi, Y Iwamoto, et al.: Reduced expression of SMARCB1/INI1 protein in synovial sarcoma. Mod Pathol. (23): 981-990, 2010.
      R Nakayama, H Morioka, et al.: Gene expression profiling of synovial sarcoma: distinct signature of poorly differentiated type. Am J Surg Pathol. 34(11): 1599-1607, 2010.
      T Shimizu, H Morioka, et al.: c-MYC overexpression with loss of Ink4a/Arf transforms bone marrow stromal cells into osteosarcoma accompanied by loss of adipogenesis. Oncogene. 29(42): 5687-5699, 2010.
      R Nakayama, J Toguchida, et al.: Gene expression profiling of synovial sarcoma: distinct signature of poorly differentiated type. Am J Surg Pathol. 34(11): 1599-1607, 2010.
      T Sasaki, T Ozaki, et al.: Preclinical Evaluation of Telomerase - Specific Oncolytic Virotherapy for Human Bone and Soft Tissue Sarcomas. Clin Cancer Res. 17(7): 1828-1838, 2011.
      M Furu, J Toguchida, et al.: Identification of AFAP1L1 as a prognostic marker for spindle cell sarcomas. Oncogene. 30: 4015-4025, 2011.
      N Setsu, S Matsuda, Y Iwamoto, et al.: The Akt/Mammalian Target of Rapamycin Pathway Is Activated and Associated With Adverse Prognosis In Soft Tissue Leiomyosarcomas. Cancer. 15;118(6): 1637-1648, 2012.
      WT van der Graaf, N Araki, et al.: EORTC Soft Tissue and Bone Sarcoma Group; PALETTE study group. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 19;379(9829): 1879-1886, 2012.
      S Kawaguchi, J Toguchida, et al.: SYT-SSX breakpoint peptide vaccines in patients with synovial sarcoma: A study from the Japanese Musculoskeletal Oncology Group. Cancer Sci. 103(9): 1625-1630, 2012.
      T Nakamura, A Matsumine, et al.: Clinical significance of pretreatment serum C-reactive protein level in soft tissue sarcoma. Cancer. 118: 1055-1061, 2012.
      M Endo, Y Iwamoto, et al.: Prognostic significance of AKT/mTOR and MAPK pathways and antitumor effect of mTOR inhibitor in NF1-related and sporadic malignant peripheral nerve sheath tumors. Clin Cancer Res. 19(2): 450-461, 2013.
      Y Fujiwara-Okada, Y Iwamoto, et al.: Y-box binding protein-1 regulates cell proliferation and is associated with clinical outcomes of osteosarcoma. Br J Cancer. 5;108(4): 836-847, 2013.
      N Setsu, Y Iwamoto, et al.: Phosphorylation of signal transducer and activator of transcription 3 in soft tissue leiomyosarcoma is associated with a better prognosis. Int J Cancer. 132(1): 109-115, 2013.
      K Yamada, T Toguchida, et al.: EWS/ATF1 expression induces sarcomas from neural crest-derived cells in mice. J Clin Invest. 123(2): 600-610, 2013.
      Y Yoneda, T Ozaki, et al.: Truncated SSX Protein Suppresses Synovial Sarcoma Cell Proliferation by Inhibiting the Localization of SS18-SSX Fusion Protein. PLoS One. 9(10): 008, 2013.
      M Tsugita, T Ohno, et al.: Ewing Sarcoma Cells Secrete EWS/Fli-1 Fusion mRNA via Microvesicles. PLoS One. 8(10): e77416, 2013.
      T Ishikawa, H Morioka, et al.: Twist2 functions as a tumor suppressor in murine osteosarcoma cells. Cancer Sci. 104(7): 880-888, 2013.
      M Emori, T Wada, et al.: High expression of CD109 antigen regulates the phenotype of cancer stem-like cells/ cancer-initiating cells in the novel epithelioid sarcoma cell line ESX and is related to poor prognosis of soft tissue sarcoma. PLoS One. 8(12): e84187, 2013.
      S Iwata, T Hiruma, et al.: Prognostic Factors in Elderly Osteosarcoma Patients: A Multi-institutional Retrospective Study of 86 Cases. Ann Surg Oncol. 21(1): 263-268, 2014.
      Y Takahashi, Y Iwamoto, Y Oda, et al.: Activation of the Akt/mammalian target of rapamycin pathway in myxofibrosarcomas. Hum Pathol. 45(5): 984-993, 2014.
      K Miyoshi, Y Iwamoto, Y Oda, et al.: Close correlation between CXCR4 and VEGF expression and frequent CXCR7 expression in rhabdomyosarcoma. Hum Pathol. 45(9): 1900-1909, 2014.
      T Shimizu, J Toguchida, et al.: IGF2 preserves osteosarcoma cell survival by creating an autophagic state of dormancy that protects cells against chemotherapeutic stress. Cancer Res. 74(22): 6531-6541, 2014.
      H Kato, A Matsumine, et al.: Anti-Tumor Necrosis Factor Therapy Inhibits Lung Metastasis in an Osteosarcoma Cell Line. Oncology. 88(3): 139-146, 2014.
      T Nakamura, A Matsumine, et al.: Role of high-sensitivity C-reactive protein in the differentiation of benign and malignant soft tissue tumors. Anticancer Res. 34(2): 933-936, 2014.
      K Yamakado, A Matsumine, et al.: Radiofrequency ablation for the treatment of recurrent bone and soft-tissue sarcomas in non-surgical candidates. Int J Clin Oncol. 19(5): 955-962, 2014.
      S Iwata, T Hiruta, et al.: Prognostic Factors in Elderly Osteosarcoma Patients: A Multi-institutional Retrospective Study of 86 Cases. Ann Surg Oncol. 21(1): 263-268, 2014.
      S Iwata, T Yonemoto, et al.: Impact of infiltrative growth on the outcome of patients with undifferentiated pleomorphic sarcoma and myxofibrosarcoma. J Surg Oncol. 110: 707-711, 2014.
      E Kobayashi, H Morioka, et al.: MicroRNA Expression and Functional Profiles of Osteosarcoma. Oncology. 86(2): 94-103, 2014.
      T Mori, H Morioka, et al.: TNFα promotes osteosarcoma progression by maintaining tumor cells in an undifferentiated state. Oncogene. 33: 4236-4241, 2014.
      E Kozawa, Y Nishida, et al.: Multiple primary malignancies in elderly patients with high grade soft tissue sarcoma. Int J Clin Oncol. 19(2): 384-390, 2014.
      Y Nishida, et al.: High incidence of regional and in-transit lymph node metastasis in patients with alveolar rhabdomyosarcoma. Int J Clin Oncol. 19(3): 536-543, 2014.
      K Ikuta, Y Nishida, et al.: Hyaluronan expression as a significant prognostic factor in patients with malignant peripheral nerve sheath tumors. Clin Exp Metastasis. 31(6): 715-725, 2014.
      H Yasui, N Araki, et al.: Tailored therapeutic strategies for synovial sarcoma: receptor tyrosine kinase pathway analyses predict sensitivity to the mTOR inhibitor RAD001. Cancer Lett. 347(1): 114-122, 2014.
      T Wakamatsu, H Yoshikawa, et al.: Deflection of VEGF action by SS18-SSX and composite VEGF- and CXCR4-targeted therapy in synovial sarcoma. Cancer Sci. 105: 1124-1134, 2014.
    4. 総説・解説
      J Toguchida, et al.: Molecular genetics of sarcomas: Applications to diagnoses and therapy. Cancer Sci. 100(9): 1573-1580, 2009.
      N Naka, N Araki, et al.: Synovial sarcoma is a stem cell malignancy. Stem Cells. 28: 1119-1131, 2010.
      岩本幸英: 悪性骨腫瘍、整形外科専門医テキスト. 南江堂. 365-372, 2010.
      小田義直、岩本幸英、他: 生検標本による軟部肉腫の組織型・悪性度判定における病理診断の問題点. 日整会誌. 84: 1114-1119, 2010.
      蛭田啓之、松本誠一、他: 骨肉腫術前化学療法の組織学的効果判定. 整形外科. 61(8): 764-768, 2010.
      田仲和宏: 非円形細胞軟部肉腫に対する化学療法. 整形外科. 61: 821-825, 2010.
      大野貴敏: 悪性軟部腫瘍の治療. 臨床整形外科. 第45巻第3号: 235-240, 2010.
      中馬広一: 3章 骨肉腫. 小児がん診療ガイドライン2011年版. 金原出版. 97-137, 2011.
      蛭田啓之、松本誠一、他: 軟部肉腫の組織学的治療効果判定と切除縁評価. 軟部腫瘍、腫瘍病理鑑別診断アトラス. 文光堂. 246-254, 2011.
      Y Iwamoto, K Tanaka: The activity of the Bone and Soft Tissue Tumor Study Group of the Japan Clinical Oncology Group. Jpn J Clin Oncol. 42: 467-470, 2012.
      田仲和宏: 悪性軟部腫瘍における化学療法の意義. 癌と化学療法. 39: 378-380, 2012.
      平賀博明: 悪性骨腫瘍; 骨・軟部腫瘍、新臨床腫瘍学 改訂第3版. 南江堂. 489-493, 2012.
      比留間徹: 骨軟部腫瘍の化学療法. がん化学療法. 66-69, 2012.
      S Matsumoto: Current and future aspects of the Japanese medical system in the treatment of musculoskeletal tumors. J Orthop Sci. (18): 505-508, 2013.
      田仲和宏: 軟部腫瘍の化学療法. 関節外科. 32: 670-677, 2013.
      田仲和宏: 整形外科における臨床試験のデザインのあり方. 臨床整形外科. 48: 1017-1024, 2013.
      中馬広一: 骨・軟部腫瘍Current Organ Topics. 癌と化学療法. 40(3): 296-298, 2013.
      吉川秀樹: 骨・軟部腫瘍、臨床病態学3 第2版. ヌーベルヒロカワ出版. 63: 179-192, 2013.
      N Araki: New practical approach against sarcoma. J Orthop Sci. 19(3): 377-378, 2014.
      蛭田啓之、他: 骨肉腫の治療効果判定と問題点. 病理と臨床. 32(2): 156-160, 2014.
      石井武彰、小田義直、他: 骨・軟部の未分化肉腫いわゆるMFHの概念の変遷. 臨床画像. 30(7): 724-729, 2014
      山口岳彦: WHO分類 骨腫瘍2013の改訂について. 病理と臨床. 32: 120-127, 2014.
  2. 主な学会発表
    1. 委員会承認の治療研究
      田仲和宏、岩本幸英: JCOG骨軟部腫瘍グループにおける「高悪性度非円形細胞軟部肉腫に対するIFO+ADRによる術前術後補助化学療法の第Ⅱ相臨床試験」. 第40回日本整形外科学会骨・軟部腫瘍学術集会. 2007年7月.
      K Tanaka, Y Iwamoto, et al.: Adjuvant and neoadjuvant chemotheraddy (NAC) with ifosfamide (IFO) and Adriamycin (ADM) for high-grade soft tissue sarcomas (STS) in the extremities: Japan Clinical Oncology Group Study JCOG0304. Annual Meeting of American Society of Clinical Oncology. Jun 2011.
      田仲和宏、岩本幸英、他: JCOG骨軟部腫瘍グループにおける多施設共同臨床試験の実践体制. 第44回日本整形外科学会骨・軟部腫瘍学術集会. 2011年7月.
      田仲和宏、岩本幸英、他: 軟部肉腫に対する化学療法の多施設共同臨床試験(JCOG study). 第85回日本整形外科学会学術総会. 2012年5月.
      田仲和宏、岩本幸英、他: JCOG骨軟部腫瘍グループの歩み. 第50回日本癌治療学会学術集会. 2012年10月.
      平賀博明、田仲和宏、岩本幸英、他: JCOGプロジェクトから見た化学療法の展望. 第86回日本整形外科学会学術総会. 2013年5月.
      田仲和宏、岩本幸英、他: JCOG主導での骨・軟部腫瘍治療薬の開発. 第51回日本癌治療学会学術集会. 2013年10月.
      K Tanaka, Y Iwamoto, et al.: Prognostic factors for high-grade soft tissue sarcomas (STS) in the extremities treated by perioperative chemotherapy with ifosfamide (IFO) and adriamycin (ADM): Using data from Japan Clinical Oncology Group trial (JCOG0304). 2014 Annual Meeting of American Society of Clinical Oncology. Jun 2014.
      K Tanaka: Multicenter clinical trials for sarcomas in Bone and Soft Tissue Tumor Study Group (BSTTSG) of Japan Clinical Oncology Group (JCOG): Difficulties and future direction. The 1st International Symposium on Recent Global Advances in Cancer Research. Feb 2015.
      田仲和宏、岩本幸英、他: 高悪性度軟部肉腫に対する補助化学療法の臨床試験(JCOG0304)における予後因子解析. 第52回日本癌治療学会学術集会. 2014年8月.
    2. グループ代表者管理の治療研究
      田仲和宏、岩本幸英、他: 悪性骨軟部腫瘍に対するGEM+DOC療法. 第86回日本整形外科学会学術総会. 2013年5月.
      長谷川匡、田仲和宏、岩本幸英、他: MIB-1 grading systemとFNCLCC grading systemの比較. 第46回日本整形外科学会骨・軟部腫瘍学術集会. 2013年7月.
      荒木信人、田仲和宏、岩本幸英、他: 骨転移に対する手術治療戦略:JCOG骨軟部腫瘍グループでのアンケート調査結果を中心に. 第52回日本癌治療学会学術集会. 2014年8月.
    3. 附随研究等
      Y Morimoto, T Ozaki, et al.: Response Evaluation Criteria in Solid Tumor (RECIST) in Soft Tissue Sarcoma of Extremity. 15th Annual Meeting of Connective Tissue Oncology Society. Nov 2009.
      Y Morimoto, T Ozaki, et al.: SNP in FGFR4 at codon 388 is still correlated with overall survival in high-grade soft tissue sarcoma over five years followup. 16th Annual Meeting of the Connective Tissue Oncology Society. Nov 2010.
      T Tsukahara, T Wada, et al.: Scythe/BAT3 regulates apoptotic cell death induced by the osteosarcoma antigen PBF in human osteosarcoma. 16th Annual Meeting of the Connective Tissue Oncology Society. Nov 2010.
      S Kawaguchi, T Wada, et al.: Clinical and immunologic responses of synovial sarcoma patients treated with SYT-SSX fusion gene-derived peptide vaccines. 16th Annual Meeting of the Connective Tissue Oncology Society. Nov 2010.
      S Tamaki, J Toguchida, et al.: Genetic and epigenetic regulation of synovial sarcoma-associated molecule, FZD10. 16th Annual Meeting of the Connective Tissue Oncology Society. Nov 2010.
      N Hashimoto, H Yoshikawa, et al.: A Phase I/II Study of Immunotherapy Targeting WT1 Peptide in Patients with Advanced/Metastatic Bone and Soft-tissue Sarcomas. 16th Annual Meeting of the Connective Tissue Oncology Society. Nov 2010.
      K Horiuchi, H Morioka, et al.: A novel multi-kinase inhibitor, Pazopanib, suppresses growth of synovial sarcoma cells through inhibition of the PI3K-AKT pathway. 17th Annual Meeting of the Connective Tissue Oncology Society. Oct 2011.
      K Hayakawa, J Toguchida, et al.: Application of iPS cell technology for the analysis of origin-unknown sarcoma characterized by a specific fusion gene. The 17th Annual Meeting of the Connective Tissue Oncology Society (CTOS). Nov 2012.
      J Hasei, T Ozaki, et al.: p53-mediated apoptotic signaling overcomes the resistance to oncolytic adenovirus in human osteosarcoma cells. 104th Annual Meeting of American Association for Cancer Research (AACR). Apr 2012.
      E Kobayashi, H Morioka, et al.: MicroRNA expression and functional profiles of osteosarcoma. The 17th Annual Meeting of the Connective Tissue Oncology Society(CTOS). Nov 2012.
      S Tamaki, J Toguchida, et al.: SS18-SSX is a cell-context-dependent epigenetic regulator: implication for cell-of-origin of synovial sarcomas. 18th Annual Meeting of the Connective Tissue Oncology Society(CTOS). Oct 2013.
      M Fukuta, J Toguchida, et al.: Establishment and differentiation of pluripotent stem cells containing drug-inducible SS18-SSX gene. 18th Annual Meeting of the Connective Tissue Oncology Society(CTOS). Oct 2013.
      T Yonemoto, et al.: Osteosarcoma occurring as second malignancy of childhood cancers (HOPES006). 18th Annual meeting of Connective Tissue Oncology Society. Oct 2013.
      H Urakawa, Y Nishida, et al.: Perioperative chemotherapy with doxorubicin and ifosfamide for bone sarcomas in adult and older patients. 18th Annual meeting of Connective Tissue Oncology Society. Oct 2013.
      Y Naito, A Kawai, K Isu, et al.: Phase II study of eribulin mesylate in patients with advanced soft tissue sarcoma (STS). 2014 Annual Meeting of American Society of Clinical Oncology. Jun 2014.
      S Hineno, J Toguchida, et al.: Involvement of epigenetic mechanism in the formation of epithelial structure of synovial sarcoma. 19th Annual Meeting of Connective Tissue Oncology Society. Oct 2014.
      S Tamaki, J Toguchida, et al.: Celluler context is important factor for the SS18-SSX-Mediated transcriptional regulation. 19th Annual Meeting of Connective Tissue Oncology Society. Oct 2014.
      K Kikuta, H Chuuman, A Kawai, et al.: An analysis of clinicopathological fractures related to the tail-like pattern of myxofibrosarcoma on MRI. 19th Annual Meeting of Connective Tissue Oncology Society. Oct 2014.
      Y Yamakawa, T Ozaki, et al.: Combination therapy of telomerase-specific oncolytic adenovirus and zoledronic acid in human osteosarcoma cells. The 105th Annual Meeting of the American Association for Cancer Research. May 2014.
      T Yonemoto, N Araki, T Sugiura, et al.: Intra-and inter-patient comparison of efficacy between two phase II studies of trabectedin (T) in patients (pts) with translocation-related sarcomas (TRS); a randomized comparative study (study-C) and a single arm study (study-S). 39th European Society for Medical Oncology (ESMO) Congress. Sep 2014.
      T Ueda, N Araki, A Kawai, et al.: Stratified efficacy analysis and pharmacokinetic (PK) analysis of tarbectedin from a randomized phase II study comparing trabectedin and best supportive care (BSC) in patients (PTS) with translocation-related sarcomas (TRS). 19th Annual Meeting of Connective Tissue Oncology Society. Oct 2014.
      H Urakawa, Y Nishida, et al.: Postoperative brain metastases in soft tissue sarcomas. 19th Annual Meeting of Connective Tissue Oncology Society. Oct 2014.
    4. 総説・解説
      Y Iwamoto: Recent advance in the treatment of bone and soft tissue sarcomas. The combined academic conference of 16th Asia-Pacific Orthopaedic Association (APOA) and the 59th Annual meeting of Taiwan Orthopaedic Association (TOA). Nov 2010.
      J Toguchida, et al.: In vivo tumor forming-signature of human osteosarcoma cells revealed by genome-wide expression profiling. 8th International Society for Stem Cell Research. Jun 2010.
      戸口田淳也: 肉腫の分子生物学. 第83回日本整形外科学会学術総会. 2010年5月.
      Y Iwamoto: Current status and perspectives on treatments for musculoskeletal sarcomas. Asia-pacific orthopaedic symposium in 2012 Annual Fall Congress of the Korean Orthopaedic Association. Oct 2012.
      中馬広一: 悪性骨・軟部腫瘍に対する標準治療と新規薬物研究の最新動向. 第51回日本癌治療学会学術集会. 2013年10月.
      戸口田淳也、他: 肉腫発生機構に関する多能性幹細胞からのアプローチ. 第72回日本癌学会総会. 2013年10月.
      Y Oda: Immunohistochemistry in mesenchymal tumorurs- An update. Recent advances in soft tissue and bone pathology. Companion meeting: International society of bone and soft tissue pathology. 102nd USCAP Annual Meeting. Mar 2013.
      J Toguchida: Application of pluripotent stem cell for sarcoma research. The 1st International Symposium on Recent Global Advances in Cancer Research. Feb 2015.
      Y Oda: Soft tissue tumors including entities currently under discussion. The 98th Annual Meeting of the German Society of Pathology. Jun 2014.
      岩本幸英: 骨・軟部肉腫の治療の進歩. 第122回中部日本整形災害外科学会・学術集会. 2014年4月.
      戸口田淳也、他: 新規治療戦略の開発をめざした肉腫起源細胞の探索. 第87回日本整形外科学会学術総会. 2014年5月.
      小田義直: 軟部腫瘍の2013年新WHO分類. 第47回日本整形外科学会骨・軟部腫瘍学術集会. 2014年7月.
      荒木信人: 骨・軟部腫瘍の過去現在未来. 第47回日本整形外科学会骨・軟部腫瘍学術集会. 2014年7月.
      小田義直: 骨腫瘍における新WHO分類の変更点:骨軟部腫瘍の新WHO分類. 2014年国際病理アカデミー日本支部教育シンポジウム. 2014年11月.
トップへ戻る